enGene Holdings Inc. (NASDAQ:ENGN) Receives $22.38 Consensus Target Price from Analysts

enGene Holdings Inc. (NASDAQ:ENGN) has been assigned an average recommendation of “Moderate Buy” from the ten research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $22.3750.

Several analysts have recently commented on ENGN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of enGene in a research note on Tuesday, October 14th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of enGene in a research note on Wednesday, December 3rd. Oppenheimer restated an “outperform” rating and set a $33.00 target price (up previously from $30.00) on shares of enGene in a research report on Wednesday, November 12th. Morgan Stanley raised their price target on enGene from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Wednesday, November 12th. Finally, Raymond James Financial upgraded enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 price objective for the company in a research report on Tuesday, November 11th.

enGene Stock Performance

Shares of NASDAQ:ENGN opened at $8.30 on Friday. The business has a fifty day moving average of $8.12 and a 200-day moving average of $6.39. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.30 and a current ratio of 6.30. enGene has a twelve month low of $2.65 and a twelve month high of $11.14. The firm has a market cap of $556.02 million, a PE ratio of -3.62 and a beta of -0.29.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.18). On average, equities research analysts predict that enGene will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On enGene

Several large investors have recently bought and sold shares of the business. Braidwell LP bought a new stake in shares of enGene during the 3rd quarter valued at $15,479,000. Affinity Asset Advisors LLC bought a new stake in enGene in the second quarter valued at about $280,000. Citadel Advisors LLC increased its holdings in enGene by 153.3% in the third quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock valued at $399,000 after purchasing an additional 35,327 shares during the last quarter. Hudson Bay Capital Management LP acquired a new position in enGene in the third quarter valued at about $76,000. Finally, Paloma Partners Management Co bought a new position in enGene during the second quarter worth about $38,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.